Aurobindo Pharma (NSE:AUROPHARMA, BOM:524804) said a US Food and Drug Administration inspection of its Unit-IV API manufacturing facility in Andhra Pradesh, India, concluded with zero observations.
The inspection was conducted from Sept. 7 to Sept. 11 at the facility operated by wholly owned subsidiary Apitoria Pharma, according to an Indian bourse filing by the pharma company.